Precision Neuroprotection and Editing Platform for Neurodegenerative Diseases

A next-generation platform integrating machine learning, gene editing, and targeted nanoparticle delivery to revolutionize the diagnosis and treatment of neurodegenerative diseases, such as ALS and FTD.

The original patent disclosed the inhibition of dipeptide repeat proteins (DRPs) using Type I PRMT inhibitors, which has limitations in terms of precision diagnosis, treatment efficacy, and patient-specific variability. The new inventive concept addresses these limitations by envisioning a comprehensive platform that combines advanced diagnostic tools, precision gene editing, and targeted neuroprotective agents to provide personalized treatment strategies for patients with neurodegenerative diseases.

The platform consists of four interconnected modules: (1) a machine learning module trained on a dataset of DRP profiles to identify specific patterns correlated with disease progression and predict optimal treatment strategies; (2) a CRISPR-Cas9 system for in vivo editing of the C9ORF72 gene to correct the GGGGCC repeat expansion and prevent DRP toxicity; (3) a nanoparticle-formulated Type I PRMT inhibitor engineered to cross the blood-brain barrier and selectively target motor neurons; and (4) a personalized medicine platform that generates customized treatment plans based on patient-specific DRP profiles. The platform enables the creation of disease-modeling iPSC lines for drug discovery and development.

The new inventive concept introduces a paradigm shift in the treatment of neurodegenerative diseases by integrating machine learning, gene editing, and targeted nanoparticle delivery to provide personalized treatment strategies. The invention is novel and non-obvious in its combination of advanced diagnostic tools, precision gene editing, and targeted neuroprotective agents, which overcome the limitations of the original patent.

Alternative embodiments of the platform could include the use of different machine learning algorithms, gene editing tools, or nanoparticle formulations. Variations of the platform could also be developed for specific neurodegenerative diseases, such as Alzheimer's disease or Parkinson's disease.

The precision neuroprotection and editing platform has significant commercial potential in the pharmaceutical and biotechnology industries, with a projected market size of over $10 billion by 2025. The platform could be licensed to pharmaceutical companies, biotech startups, or research institutions, and could also be used to develop new business models for personalized medicine and precision healthcare.